Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pfizer (GB:0Q1N)
LSE:0Q1N
Holding GB:0Q1N?
Track your performance easily
0Q1N Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$24.49 - $31.73
Previous Close$25.65
Volume64.56K
Average Volume (3M)378.35K
Market Cap
$145.36B
Enterprise Value$203.38B
Total Cash (Recent Filing)$9.95B
Total Debt (Recent Filing)$67.70B
Price to Earnings (P/E)34.5
Beta0.37
Next Earnings
Feb 04, 2025EPS Estimate
$0.48Last Dividend Ex-Date
Nov 08, 2024Dividend Yield6.64%
Share Statistics
EPS (TTM)0.74
Shares Outstanding5,666,990,035
10 Day Avg. Volume1,771
30 Day Avg. Volume378,349
Standard Deviation0.06
R-Squared0.20
Alpha-0.00703
Financial Highlights & Ratios
Price to Book (P/B)1.88
Price to Sales (P/S)2.37
Price to Cash Flow (P/CF)5.30
P/FCF Ratio5.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.38
Enterprise Value/Gross Profit6.06
Enterprise Value/Ebitda13.34
Forecast
1Y Price Target
$32.14Price Target Upside25.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Pfizer News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceShares are considered undervalued given potentially better fundamentals relative to U.S. BioPharma peers, with potential top-line growth and margin expansion underappreciated.
Leadership And Strategic DirectionThe company may announce a new Chief Scientific Officer soon, potentially bringing fresh leadership and strategic direction.
Market Opportunities And GrowthPonsegromab could unlock large market opportunities in cancer cachexia and potentially other diseases.
Bears Say
Clinical Trial DelaysPfizer recently upsized and delayed ponsegromab’s Ph2 trial, including changing the estimated primary completion date from March 2025 to March 2026.
Financial PerformancePfizer has underperformed versus peers.
Revenue GrowthThe true driver of value creation for Pfizer will be revenue growth, and not enough mega-blockbusters in Pfizer's new product cycle are counted to fill the revenue hole from upcoming patent expirations.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.03% Insiders
18.96% Mutual Funds
11.35% Other Institutional Investors
49.45% Public Companies and
Individual Investors
0Q1N FAQ
What was Pfizer’s price range in the past 12 months?
Pfizer lowest share price was $24.49 and its highest was $31.73 in the past 12 months.
What is Pfizer’s market cap?
Currently, no data Available
When is Pfizer’s upcoming earnings report date?
Pfizer’s upcoming earnings report date is Feb 04, 2025 which is in 73 days.
How were Pfizer’s earnings last quarter?
Pfizer released its earnings results on Oct 29, 2024. The company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.614 by $0.446.
Is Pfizer overvalued?
According to Wall Street analysts Pfizer’s price is currently Undervalued.
Does Pfizer pay dividends?
Pfizer pays a Quarterly dividend of $0.42 which represents an annual dividend yield of 6.64%. See more information on Pfizer dividends here
What is Pfizer’s EPS estimate?
Pfizer’s EPS estimate is $0.48.
How many shares outstanding does Pfizer have?
Pfizer has 5,666,990,000 shares outstanding.
What happened to Pfizer’s price movement after its last earnings report?
Pfizer reported an EPS of $1.06 in its last earnings report, beating expectations of $0.614. Following the earnings report the stock price went down -1.558%.
Which hedge fund is a major shareholder of Pfizer?
Among the largest hedge funds holding Pfizer’s share is Diamond Hill Capital Management Inc. It holds Pfizer’s shares valued at 479M.
---
Pfizer Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.14 (25.30% Upside)
$32.14 (25.30% Upside)
Blogger Sentiment
Bullish
GB:0Q1N Sentiment 83%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $28.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.22%
12-Months-Change
Fundamentals
Return on Equity
4.52%
Trailing 12-Months
Asset Growth
2.07%
Trailing 12-Months
Company Description
Pfizer
Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
---
0Q1N Company Deck
---
0Q1N Earnings Call
Q3 2024
0:00 / 0:00
---
0Q1N Revenue Breakdown
52.29% Primary Care
25.59% Specialty Care
19.88% Oncology
2.24% BUSINESS INNOVATION
---
0Q1N Stock 12 Month Forecast
Average Price Target
$32.14
▲(25.30% Upside)
Technical Analysis
Best Analysts Covering 0Q1N
1 Year
1 Year Success Rate
25/34 ratings generated profit
1 Year Average Return
+5.32%
initiated a buy rating 9 months ago
Copying Vamil Divan's trades and holding each position for 1 Year would result in 73.53% of your transactions generating a profit, with an average return of +5.32% per trade.
---